AI in cancer prediction, detection, and treatment: production reality in 2026

AI in oncology has moved past research demonstrations to production clinical deployment. Lung cancer detection at 86-94% accuracy (cited research). Mammography improvement of 20% in detection rates (Swedish study). FDA-cleared diagnostic assistance tools in active clinical use. The technology is real; the question for healthcare leaders is which deployments are ready for their organization today.

This article maps where AI is genuinely working in oncology, with public reference deployments and measurable outcomes. For broader healthcare AI framing, see /industries/healthcare. For deeper treatment of healthcare AI cost, see assessing the cost of implementing AI in healthcare.

Nine production AI deployments in oncology

1. Early lung cancer detection from CT scans

AI models analyze CT scans to identify subtle patterns invisible to human radiologists. Research deployments reach 86-94% accuracy on next-year cancer development risk prediction.

Impact: earlier intervention, better outcomes per dollar treated, higher survival rates. Lung cancer caught at Stage 1 has 5-year survival ~60%; caught at Stage 4, ~5%.

2. Breast cancer screening augmentation

AI as concurrent reader on mammograms improves detection rates substantially. Published Swedish study showed 20% detection rate improvement with identical false-positive rates compared to two-radiologist baseline.

Reference deployments: various FDA-cleared mammography AI tools in active clinical use. The architectural pattern that succeeds: AI as second reader, not replacement, with explicit clinician oversight.

Impact: earlier breast cancer detection, fewer missed diagnoses, comparable false-positive rates.

3. Pathology image analysis

AI augments pathologists by analyzing tissue samples for cancer indicators. Particularly valuable in dermatology, where AI-assisted melanoma detection reaches dermatologist-level accuracy.

Reference deployments: PathAI's diagnostic platform, Google's pathology AI tools, IBM Watson Health.

Impact: faster pathology results, more comprehensive analysis of tissue samples, second-opinion confidence.

4. Brain tumor classification during surgery

Real-time tumor classification during neurosurgery enables surgeons to adjust approach based on tumor type. Reference deployment: UMC Utrecht's intra-operative classification tool correctly classified 45 of 50 frozen samples; appropriately refused recommendation on 5 ambiguous cases.

Impact: surgical decisions informed by tumor biology in real-time, better patient outcomes.

5. Personalized treatment recommendations

AI analyzes patient genomics, medical history, and similar-patient outcomes to recommend personalized cancer treatment paths. IBM Watson for Oncology matched expert recommendations in 96% of test cases.

Production patterns: AI as decision support augmenting clinician judgment with comprehensive data integration. Final treatment decisions stay with the oncology team.

Impact: more personalized treatments, better outcomes per dollar, reduced treatment failure rates.

6. Drug discovery for cancer therapeutics

AI accelerates discovery of novel cancer therapies — identifying molecular targets, predicting drug-target interactions, optimizing molecular structures.

Reference deployments: AlphaFold for protein structure (Nobel Prize 2024), Recursion's AI drug discovery platform, BenevolentAI's drug repurposing platform.

Impact: faster drug discovery, lower R&D cost per approved therapy, expanded druggable target landscape.

7. Clinical trial patient matching

AI matches cancer patients to relevant clinical trials based on genomic profile, disease characteristics, geographic accessibility, and trial criteria.

Production patterns: RAG over trial registry + patient EHR + scientific literature, with clinician validation of matches.

Impact: higher trial enrollment, better trial-patient fit, faster drug development.

8. Risk stratification for treatment planning

AI identifies which patients are at highest risk of disease progression, treatment complications, or recurrence. Enables targeted resource allocation and intervention.

Reference deployments: various FDA-cleared risk scoring tools in clinical use.

Impact: more efficient resource allocation, better outcomes for high-risk patients, reduced unnecessary intervention for low-risk patients.

9. Radiation therapy planning

AI optimizes radiation therapy dose distribution, treatment field design, and motion management. Reduces planning time from days to hours while improving plan quality.

Reference deployments: RaySearch Laboratories, Varian Eclipse, Elekta Monaco — all incorporate AI for treatment planning.

Impact: better tumor coverage, reduced radiation to healthy tissue, faster treatment planning.

What separates production from pilot in oncology AI

FDA pathway for SaMD-classified tools

Diagnostic AI tools fall under FDA Software as a Medical Device (SaMD) pathway. 510(k) clearance or De Novo pathway adds 12-24 months and $200K-$1M+ in regulatory work for diagnostic claims. Most early oncology AI deployments scope below the SaMD threshold (information-only output, decision support not autonomous decisions) to avoid this overhead.

Clinical validation studies

Beyond regulatory pathway, real-world validation is non-negotiable. Studies measuring outcomes against clinician baselines on representative patient populations. Plan $50K-$500K+ for meaningful validation.

Integration with EHR and PACS

Oncology AI deployments need integration with electronic health records (Epic, Cerner), imaging systems (PACS), and clinical workflow tools. Integration routinely consumes 30-40% of project budget.

Continuous monitoring and retraining

Cancer biology evolves. Treatment standards change. Models drift. Production oncology AI requires:

• Performance monitoring against ongoing outcomes
• Retraining cycles as new data accumulates
• Regulatory documentation of model updates
• Clinical sign-off on material changes

HIPAA and patient privacy

PHI handling requires standard HIPAA compliance plus oncology-specific considerations (genomic data privacy, family member implications, research data sharing).

What's deployable today vs what's still pilot

Production-ready in 2026:

• Diagnostic AI for narrow conditions with FDA clearance
• Treatment planning AI for radiation therapy
• Pathology image analysis as second reader
• Clinical trial matching tools
• Documentation and reporting AI

Pilot-stage requiring clinical validation:

• Multi-modal AI combining imaging + genomics + EHR
• Foundation model-driven oncology assistants
• Personalized therapy recommendation systems
• Continuous-learning AI in clinical workflow

Wait for further regulatory clarity:

• Fully autonomous cancer diagnosis without specialist review
• AI-driven treatment decisions in regulated workflows without HITL
• Cross-jurisdiction deployments where regulatory regimes conflict

Final framing

AI in oncology delivers measurable patient outcomes when deployed with discipline. The cancer centers leading in their regions by 2027 will be those investing now in disciplined AI deployment — not chasing every announcement, not waiting for "perfect" technology.

The teams that succeed in oncology AI treat it as production engineering with clinical validation, regulatory awareness, and operational discipline. The competitive advantage compounds — each successful narrow deployment builds infrastructure and trust for the next, broader application.

---

Ready to scope an oncology AI project? Run the Project Estimator for a deterministic ballpark, or book a 45-minute Discovery with our healthcare AI engineers — we'll review your imaging modalities, clinical workflows, and regulatory constraints, and tell you honestly which deployments are ready for clinical validation.